With the arrival of AstraZeneca's (AZN -0.4%) new CEO, and the company heading towards a steep...


With the arrival of AstraZeneca's (AZN -0.4%) new CEO, and the company heading towards a steep patent cliff, speculation is rising over the company's potential targeting of takeover candidates, with Forest Labs (FRX) being bounced around by Street analysts as the most tempting target. Leerink Swann says AZN has the cash, and FRX has one of the best pipeline hit rates around and is spending hard on R&D. Exane agrees, adding that the two company's have "more than a significant overlap in certain product areas.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs